Understanding Treatment
Response Heterogeneity
Intra-patient heterogeneity is nearly universal in cancer.1. Having as few at 9% of lesions not responding to therapy can result in significantly worse outcomes.2,3
SUVhetero is an imaging metric of intra-patient heterogeneity. Change in SUVhetero was the most significant predictor of time to PSA progression (hazard ratio [HR], 3.88; 95% CI, 1.24 to 12.1) and time to treatment discontinuation (HR, 4.21; 95% CI, 1.28 to 13.8) in a study of men with progressive metastatic castration-resistant prostate cancer (mCRPC).3
1. Meacham et al, Nature, 2013; 2. Harmon et al., J Clin Oncol 2017, including unpublished supplemental data analysis; 3. Kyriakopoulos et al, J Clin Oncol 2020.
TRAQinform IQ Technology
TRAQinform IQ is AI-driven software that provides novel information about treatment response.
Oncologists use this technology to more precisely adjust therapies and optimize clinical outcomes.
 TRAQinform IQ uses serial radiographic images (e.g., PET, CT) |
 |
 Images are uploaded via the cloud to AIQ solutions (HIPAA compliant) |
|
 AI-driven software provides novel, quantitative and spatial information about each region of interest |
|
 A comprehensive report is generated and delivered to the oncologist |
|
 Oncologists can use the information to tailor treatment regimens and optimize outcomes |
Clinical Application: Making Confident Treatment Decisions
TRAQinform IQ works with all therapy types including immunotherapy, chemotherapy,
radiation therapy, targeted therapy and hormone therapy.
